Researchers at the Dana-Farber Cancer Institute believe that pairing two immunotherapies might be a big contender in combating malignant pleural mesothelioma.

Combining Immunotherapy Drugs

This phase 2 study is combining the immunotherapy drugs durvalumab and tremelimumab. Both of these drugs have had success in combating other forms of cancer. The two drugs have also been used separately to combat and treat mesothelioma, but this will be the first time that they will be used together.

Treatments in This Trial

  • Durvalumab (CP-675,206) is a PD-L1 inhibitor. This drug aids the immune system in finding cancer cells that are hiding in the body. Durvalumab is known to block PD-L1, a protein that is often produced by cancer cells or surrounding cells to suppress immune cells from attacking cancer cells.
  • Tremelimumab (MEDI-4736) – is a CTLA-4 antibody. This drug aids in boosting the immune system. Tremelimumab is known to block CTLA-4, a receptor on immune cells which normally suppresses immune attack.

Researchers believe that both of these immunotherapy drugs work in similar ways. They anticipate that tremelimumab will help improve the effect that durvalumab has on combating cancer cells. If researchers are correct, the combination of these two immunotherapy drugs will slow the growth of cancer cells and kill them.

Get Help Enrolling in This Trial

This trial combines two previously tested immunotherapy drugs. Immunotherapies work with your immune system to fight cancer. If you are looking for a new treatment option, this trial may be for you.

Benefits of choosing this trial:
  • Receive innovative immunotherapies
  • Get treatment at a top cancer center
  • Alternative to standard chemotherapy




About The Trial

The goal of this clinical trial is to test the safety and the effectiveness of both durvalumab and tremelimumab. Researchers are studying the combination of these two immunotherapy drugs and are comparing their findings to the usual approaches that are used for treating malignant pleural mesothelioma.

What to Expect

Participants in this trial will receive both durvalumab and tremelimumab via intravenous infusion. Participants will receive these infusions every 28 days. Tremelimumab will be given to each participant for only 4 cycles, but participants will continue to receive durvalumab until they have completed the study.

Location: Dana-Farber Cancer Institute

Image of Brigham and Women's HospitalThis trial is occurring at the Dana-Farber Cancer Institute, an institute at Brigham & Women’s Hospital in Massachusetts. If a patient isn’t a local to the area, they might have to make travel and lodging arrangements to accommodate them while they are participating in the study, considering participants will be receiving a treatment infusion every 28 day cycle.

Head of Trial: Dr. Mark Awad

Mark Awad, photo from Brigham and Women's HospitalDr. Mark Awad is a thoracic oncologist at the Dana-Farber Cancer Institute. His research consists of understanding the mechanisms of both response and resistance to immunotherapy in lung cancer and mesothelioma. He is both strongly involved and dedicated to developing novel therapies for lung cancers with specific genetic mutations.

Who is This Trial For?

Eligibility

To qualify for this clinical trial a participant must:

  • Be diagnosed with malignant pleural mesothelioma
  • Have inoperable disease
  • Have been treated with first-line chemotherapy without success

Patients must also be willing to undergo a biopsy at the beginning of their treatment and they must be willing to undergo a biopsy while they are receiving their treatment.

Exclusions

For the safety of participants in this clinical trial, there are some circumstances that will make a patient ineligible to participate. To be accepted into this clinical trial a patient must not have participated in previous treatments that included an immune checkpoint inhibitor. They must not have had any prior treatments with either durvalumab or tremelimumab drugs.

Participants that have an uncontrollable illness such as, infection, heart failure or gastritis are not eligible to participate in this clinical trial. Patients must also wait at least 28 days after a major surgery to participate in this trial. These are just a few of the study’s notable exclusions. For more information about what other exclusions there are, please contact Mesothelioma Guide.

Is This Trial For You?

The Dana-Farber Cancer Institute is a partner of Brigham & Women’s Hospital. The institute shares several departments with the hospital. Brigham & Women’s Hospital is home to the International Mesothelioma Program (IMP). IMP has over 20 years of knowledge in both clinical and research experience in combating and finding a cure for mesothelioma.

If you are interested in this clinical trial, we are available to answer any questions that you may have. We are here to help you get connected to the right trial for you.